Ponezumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ponezumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetbeta-amyloid
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6552H10158N1730O2090S52
Molar mass148.3 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1]

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.[2] Detailed reports have to be released.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
  2. ^ "Alzforum".